Ignite Creation Date:
2025-12-25 @ 4:58 AM
Ignite Modification Date:
2025-12-26 @ 3:58 AM
Study NCT ID:
NCT04184518
Status:
WITHDRAWN
Last Update Posted:
2020-06-02
First Post:
2019-11-29
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma
Sponsor:
Grupo Español Multidisciplinar de Melanoma
Organization:
Study Overview
Official Title:
Phase II, Open-Label Study of Preliminary Efficacy of Durvalumab (MEDI4736) in Combination With Cediranib in Patients With Metastatic Uveal Melanoma
Status:
WITHDRAWN
Status Verified Date:
2020-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
The Cediranib producer laboratory decided to stop the development of this product.
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CEDUVEAL-M
Brief Summary:
Phase II clinical trial aimed to evaluate the efficacy of the combination of cediranib and durvalumab in patients with metastatic uveal melanoma (mUM) with biopsiable disease at first line of after failure to first line systemic or liver directed therapy.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: